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Past
events
On 25 February 2012, an interdisciplinary scientific meeting 
on the Radiosynovectomy of Peripheral Joints (RPJ) was held 
in a lecture hall of Nukleomed clinic in Warsaw. The meeting 
was participated by a number of orthopaedists, rheumatologists, 
general practitioners and nuclear medicine specialists, including 
Prof. Jarosław Czubak from the Prof. A. Gruca Independent Public 
Clinical (CMKP) Hospital in Otwock, Prof. Leszek Królicki from 
the Medical University of Warsaw and Prof. Manfred Fisher from 
the Medical University in Kassel (Germany), who apply or wish 
to initiate radionuclide treatment of synovitis for their patients. 
The meeting was opened and hosted by Dr Krzysztof Toth from 
Nukleomed clinic in Warsaw. 
The inauguration lecture was given by Prof. Leszek Królicki 
(LK), National Consultant for Nuclear Medicine. First, Prof. Królicki 
referred to the enormous advancement in the development of new 
diagnostic methods in Europe, pointing out the advantages of 
hybrid methods, such as SPECT/CT, PET/CT and PET/MRI, over 
traditional imaging methods. He noted that today the percentage 
of scintigraphic tests is very high compared to other diagnostic 
methods used on an everyday basis in the European Union and 
that they will continue to be favoured in the future over traditional 
radiological procedures. Currently, about 50% of cardiological 
tests and 55% of skeletal system tests are scintigraphic pro-
cedures compared to other diagnostic imaging methods used 
in Europe. According to the projections based on the method 
of technopolis (aimed at forecasting the development of new 
technologies and their application in the future), there will be 
fewer tests based on traditional procedures and the percentage 
of diagnostic tests with the assistance of hybrid technologies will 
increase. The essential advantage of the latter is the capability 
of simultaneous imaging both the morphological structure and 
functioning of specific organs. 
In the second part of his presentation Prof. Królicki presented 
a historical background and guidelines of the European Associa-
tion of Nuclear Medicine (EANM) for radionuclide joint treatment. 
Scientific Meeting Report
Radiosynovectomy — radionuclide 
treatment of synovitis in the peripheral 
joints
He reminded that the essential objective of radionuclide treatment 
is to inhibit the growth of the synovial membrane by using the 
energy of beta radiation of intra-articularly administered radiocol-
loids. An isotope phagocyted by synoviocytes emits energy which 
causes the decay of over-reactive cells, thus preventing local ef-
fusions and inhibiting inflammatory factors in the joint, and finally 
alleviating pain and improving the joint kinetics. LK discussed in 
detail the properties of isotopes used for RPJ: yttrium-90, rhe-
nium-186 and erbium-169, and emphasized the importance of their 
proper selection relative to the size of the joint and thickness of 
the synovial membrane. 
The isotope-specific hardness of beta radiation deter-
mines its action within the joint. For this reason yttrium-90 
isotopes with average radiation hardness of 3.6 mm in the soft 
tissue are used for treating knee joints, rhenium-186 isotopes with 
maximum radiation hardness of 1.1 mm are used for mid-size 
joints, such as brachiocarpal, cubital, iliofemoral, tarsal or shoulder 
joints and erbium-169 isotopes with radiation hardness of 0.3 mm 
are used for small-size joints of the hand and foot. In reference to 
factors underlying the efficacy of the treatment LK focused par-
ticular attention on proper qualification of patients based on close 
cooperation between nuclear medicine physicians and clinicians. 
According to the EANM guidelines, the treatment of joints using 
radionuclides involves is only a symptomatic treatment designed 
for patients whose level of pain or other problems within the joint 
have a significant adverse impact on their mobility or require tak-
ing analgesics on a permanent basis. RPJ may be used for the 
following nosological entities:
 — rheumatoid arthritis (RA);
 — psoriatic arthritis (PA);
 — reactive spondyloarthropathies;
 — other types of arthritis, e.g. Lyme disease;
 — Behcet’s disease;
 — persistent joint effusions;
 — haemophilia;
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 — calcium pyrophosphate dihydrate disease (CPPD);
 — pigmented villonodular synovitis (PVNS);
 — persistent joint effusions following prosthetic surgery;
 — non-classified inflammatory conditions, if the major symp-
toms include inflammation, synovial thickening and effusion.
If different forms of therapy are applied, the radionuclide treat-
ment should not be used until 6 weeks after joint implementation 
and 2 weeks after joint biopsy. If it is necessary to re-administer 
a radioactive isotope, there should be a minimum time interval of 
6 months. Absolute contraindications to RPJ include pregnancy 
and breast feeding, local skin infections and Baker’s cyst rupture. 
Although a significant degree of joint instability and/or significant 
damage to joint cartilage are only relative contraindications to RPJ 
in accordance with the EANM guidelines, the treatment is practi-
cally not used in the case of patients with such problems on 
account of no analgesic effect and high risk of complications. 
The radionuclide treatment may be used for children and per-
sons under the age of 20 after careful consideration of potential 
benefits and risks of possible complications.
LK recommended ultrasound scanning and dynamic bone 
scintigraphy among the tests which should be carried out as part 
of the qualification process for RPJ. Ultrasound scanning makes it 
possible to accurately determine the synovial membrane thick-
ness and presence of effusions as well as to examine ligament 
structures of the joint, while scintigraphy makes it possible to deter-
mine physical functions of the joint synovial fluid. Greater uptake of 
the osteotropic marker in the vascular and parenchymatous phase 
supports the idea of high metabolic activity of the synovium and 
makes a good eligibility index. 
Of significant importance here is close cooperation between 
clinicians and nuclear medicine specialists because treatment 
effects depend to a great extent on the time of application the 
radionuclide method from among a range of treatment forms. 
It is important to carry out RPJ at an early stage of the degen-
erative disease and at active stages of autoimmune or reactive 
diseases. One of the newest methods used for evaluating the 
activity of the inflammatory process is scintigraphy with specific 
markers. LK referred to the studies of Martins et al. concerning 
the application of labelled anti-CD3 monoclonal antibodies and 
of Rogier et al. concerning scintigraphy with labelled monocytes. 
At least two intra-articular haemorrhages in the course of a dis-
ease are considered a clinical indication for the application of 
RPJ in the treatment of arthropathy in the course of haemophilia. 
On the other hand, Kat and Shabat recommend comprehensive 
treatment — surgery followed by adjuvant radionuclide therapy 
— for patients with pigmented villonodular synovitis. Radio-
nuclide therapy should be held in a nuclear medicine institute 
which has appropriate technical rooms and qualified personnel. 
Accurate application of radiopharmaceutical to the articular cav-
ity should be absolutely carried out under aseptic conditions. It 
is recommended that punctures should be made in the X-ray or 
USG visual track as homogenous distribution of radiocolloid in the 
joint is necessary for the therapy to be effective. Patients should 
be informed about possible intermittent intensification of pain in 
the 1st – 2nd week of treatment. Restrictive joint immobilisation for 
48 hours minimises the risk of complications, such as isotope 
moving back to the puncture channel and skin necrosis. Currently, 
a single intra-articular application of steroids (e.g. Triamcinolone 
40 mg/1 ml in the case of large and mid-size joints, 20 mg/0.5 mL 
in the case of small-size joints) is recommended.
When discussing the efficacy of isotope-based radiosynovec-
tomy, LK emphasized that it is a symptomatic treatment, and treat-
ment effects in the form of improved articular mobility, reduced 
pain and swelling, and general improvement of the quality of life 
are delayed. The first follow-up visit should be arranged after 6–8 
weeks. LK pointed out that the lack of clinical improvement after 
approximately 6 weeks from the isotope application shows that the 
results of therapy are uncertain. In some patients, a second isotope 
dose turns out to be effective. The therapy should not be re-applied 
until at least 6 months from the date of the first application.
When discussing the efficacy of radiosynovectomy, LK pointed 
out that the his own materials and literature review showed that 
better response to the treatment is achieved in the case of auto-
immune (RZS, ŁZS) and reactive (chlamydiosis, Lyme disease) 
diseases compared to degenerative arthropathies. LK referred for 
example to the study of Rau et al. („Multicenter study of radiosyn-
oviorthesis” 2004) which aimed to evaluate the impact of RPJ to 
the clinical condition and quality of life in 691 patients. The therapy 
has been observed to be most effective in patients diagnosed 
with 1st- and 2nd-stage RZS (78–80%). In the case of patients diag-
nosed with other diseases or more advanced stages of RA clinical 
improvement was observed in only 56%, and improved quality 
of life in 59% of them. LK referred also to the study of Markau 
et al. (2009) who published the results of 6-month yttrium-90 
treatment for 76 patients with intense knee pain in the course of 
degenerative joint disease. Pain was resolved in as many as 89% 
of the patients, and improved articular mobility was achieved in 
65%. The authors established that the efficacy of isotope-based 
therapy of knee joint synovitis depends on the duration of the 
disease, stage of progress and patient’s age. Better response 
was achieved in the case of younger patients with less intense 
articular lesions. Similar conclusions were published by Kresnik et 
al. (2002), while according to Farahati et al. (2002) the duration of 
arthritis does not affect the efficacy of RPJ. Significant pain relief 
was reported for 78% of the patients at various intervals from the 
onset of pain. Finally, LK pointed out that despite the application 
of radioactive substances, isotope treatment of joints is fully safe 
in terms of exposure to ionizing radiation. Professor referred to the 
study of Vuoreli et al. in which indicators of carcinogenesis were 
evaluated for patients who underwent RPJ of knee joints. The 
authors demonstrated that intra-articular application of yttrium-90 
does not contribute to the development of neoplastic diseases of 
other organs, and the indicator of cancer development for post-RPJ 
patients was twice as low compared to the control group. LK 
recapitulated that the potential of radionuclide therapy, which 
continues to be unappreciated in Poland and applied to a much 
more limited number of cases than in other European countries, 
and often enough can provide an important additional therapeutic 
option for orthopaedists, can only be fully realised by clinicians and 
nuclear medicine specialist working closely together.
The second part of the meeting featured presentations of 
radionuclide treatment results for chronic peripheral arthritis by 
physicians with extensive experience in this area.
The first presentation was held by Dr Maria Płazińska (MP), 
nuclear medicine specialist who described her own practice in the 
Nuclear Medicine Laboratory of the University Hospital in Warsaw. 
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RPJ procedure was applied in a group of 555 patients composed 
of 460 women and 95 men, where 243 patients were treated for 
chronic articular discomfort in the course of rheumatoid arthritis, 
291 — in the course of osteoarthropathy (OA), and 21 patients suf-
fered from psoriatic arthritis (PA). RPJ therapy was applied to all 
types of joints, mostly knee joints, shoulder joints, brachiocarpal 
joints and small-size joints of the hand. The isotope was adminis-
tered twice to about 2/3 of the patients. MP detailed the method-
ology of RPJ and showed a range of photographs made during 
the procedures. The efficacy evaluation of radionuclide treatment 
included the change in the synovial membrane thickness and the 
amount of effusion within the joints subject to ultrasound scan-
ning, joint swelling according to the circumference of the joint in 
cm, pain level, joint mobility and daily amount of analgesics. MP 
presented the results of knee joint treatment based on yttrium-90 
for 40 patients as evaluated after 6 and 12 months from the date of 
procedure. She pointed out that the proper effects of radionuclide 
therapy should be subject to evaluation on a delayed basis. Ac-
cording to the statistical analysis, the percentage of patients for 
whom clinical improvement was achieved totalled approximately 
75% at a 6-month interval and approximately 80% at a 24-month 
interval following the treatment.
Afterwards radionuclide treatment results for chronic synovi-
tis in knee joints were presented by Dr Bogusław Musiał (BM), 
orthopaedist, who spoke on his own and Dr Tomasz Gołąb’s be-
half. As a preliminary point BM said that the literature contains few 
reports of radionuclide joint treatment results for diseases other 
than RA and haemophilia. In the Clinica Medica Nuclear Medi-
cine Institute in Tychy, RPJ therapy was applied in 90 out of 124 
patients who underwent qualification for the procedure. The 
number of radiosynovectomy procedures based on yttrium-90 
was 89 in the case of OA patients and 12 in the case of RA pa-
tients. The efficacy evaluation of the treatment was carried out 
according to the criteria published by Blachut et al. which take 
into account the subjective impression of improvement, better 
joint mobility and recurrence of joint discomfort. Very good and 
good results were obtained for 52% of the patients suffering with 
degenerative joint disease, satisfactory results for 37%, while no 
effects were observed for 11%. The best treatment results (efficacy 
at approx. 80%) were demonstrated in the presented material 
for patients diagnosed with psoriatic arthritis, in the course of 
arthritis urica (efficacy at approx. 80%) and RA (efficacy at approx. 
60%). BM pointed out that the literature contains a large number 
of studies concerning radionuclide peripheral joint treatment in 
RA and PA, however, there are no reports of treatment results for 
degenerative joint disease, and this was a prevailing disease 
among the patients included in the presented study. BM referred 
to the report of Deutsch et al. who analysed RPJ results from 
72 German centres for patients who underwent the treatment 
because of pain in the course of RA in the years 1975–1992. Very 
good and good therapy results were achieved for 60–80% of the 
patients treated with synoviorthesis after an observation interval 
of one year or longer. 
The next presentation titled “Radiosynovectomy in orthopaedic 
practice — 3 years of experience” was held by Dr Piotr Godek (PG). 
Firstly, PG extended a thank you to Dr Toth for showing interest in 
RPJ and initiating this specific procedure into the scope of prac-
tice in the Nuclear Medicine Laboratory at the Nukleomed clinic.
During the three years of cooperation with Dr Krzysztof 
Toth at the Nukleomed clinic in Warsaw 333 radiosynovectomy 
procedures were performed in the years 2009–2011, where 290 
procedures were carried out on knee joints, 11 — on brachiocarpal 
joints, 10 — on small-size joints of the hand, 9 — on shoulder joints, 
8 — on tarsal joints, and 3 — on cubital joints. Prepatellar bursa 
treatment was attempted in two cases. Among the patients in-
cluded in the study a prevailing group of 171 patients suffered 
from intense degenerative lesions, 27 patients treated because 
of intensified articular discomfort in the course of RA, 4 — in the 
course of AS, and 1 patient with juvenile idiopathic arthritis (JIA). 
Radionuclide was injected twice in the case of 30 patients, and 
RPJ procedure was performed three times in the case of 9 pa-
tients. All patients had an ultrasound scan of the joint, including 
an evaluation of the synovial membrane thickness and the amount 
of effusion, prior to the treatment. In some patients the evalu-
ation of joint synovitis was based on the three-phase dynamic 
bone scintigraphy results. Positive qualification criteria included 
increased accumulation of the marker (HMDP-Tc99m) within the 
joint in the parenchymatous phases of scintigraphy scanning 
and/or synovial hypertrophy diagnosed based on ultrasound re-
sults. Similarly as Dr Płazińska, PK illustrated his presentation with 
photographs taken during the procedures. In each case ultrasound 
monitoring was applied at the time of radionuclide administration. 
Administration of an appropriate radionuclide to the articular cavity 
was followed by injection of glicocorticosteroid (Betametazone 
7 mg/mL). Following the procedure the joints were immobilized 
with orthoses as already mentioned proper immobilization of the 
treated joint is a necessary prerequisite for correct distribution of 
the marker in the articular cavity and prevents radioactive colloid 
from moving back to the puncture channel. All patients received 
thromboprophylactic treatment. To evaluate the efficacy of RPJ 
PG used so-called subjective assessment of patient’s satisfac-
tion which includes pain level, joint range of motion, daily activity. 
This method was used for evaluating the improvement of the quality 
of life on a scale from 0 to 100% in the case of 178 patients. Based 
on his own observations and literature data, PG determined that 
the highest efficacy of treatment was achieved in the case of JIA 
patients (improvement at 80%), and the lowest efficacy in the case 
of patients with degenerative lesions in the most advanced stage 
of the disease who had a disorder of the joint axis of symmetry 
(25%). A high level of satisfaction from the treatment was reported 
for patients with RA (70%) and reactive arthritis (60%). Based on 
an analysis of his own results, PG hypothesized that the change 
in the synovium membrane thickness during the therapy is one 
of the major predictive factors of patient’s satisfaction. According 
to his observations, patients for whom the greatest reduction in 
the synovium thickness occurred reported the best improvement 
in pain level and joint mobility. It is also important to apply the 
treatment only to joints with preserved correct alignment. During 
his presentation PG also discussed thoroughly the complica-
tions observed in his patients. There was one serious complication 
in the form of skin necrosis at the isotope application site during 
the three-year observation period. When analyzing this case, PG 
pointed out that it was one of the first female patients to receive the 
treatment. Skin necrosis occurred in the prepatellar region, most 
likely on account of the defective barrier in the form of the bursa wall 
(as opposed to the barrier in the form of the joint capsule), despite 
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the explicit synovial hypertrophy. Therefore, according to PG, the 
relatively high risk of similar complications following the application 
of an isotope outweighs any possible benefits derivable from the 
treatment of synovial bursitis. The other complications included 
minor lesions, such as 3 superficial burns, 6 point discolorations at 
the radiopharmaceutical application site, 4 cases of transient pain 
intensification within the treated joint and 1 purulent arthritis. PG 
emphasized the importance of very restrictive immobilisation of 
the treated joints. He noted that since the implementation of the 
rule that patients who underwent RPJ of the knee joint have their 
lower limb fully immobilized and are wheeled to the exit (and do 
not leave on their own) neither point skin discolorations at the 
application site nor other complications have been observed. 
When discussing these complications, PG noted the importance 
of interdisciplinary meetings and exchange of experience between 
medical centres and physicians with different specializations. PG 
is convinced that only direct contact between orthopaedists and 
nuclear medicine specialists could allow clarifying indications for 
RPJ, and thus optimizing the group of patients who could most 
benefit from the treatment. Taking advantage of the fact that in-
terdisciplinary meetings offer an opportunity to discuss specific 
clinical problems, PG requested the participants to initiate a dis-
cussion with a view to clarifying the following issues:
1. if total uncovering of the subchondral layer contributes to 
bone necrosis;
2. if the lack of non-defective joint capsule precludes the possibil-
ity of the RPJ procedure as the determination of the condition of 
the synovial bursa, e.g. in the shoulder joint, is a difficult task;
3. if the RPJ procedure should be applied in the treatment of 
popliteal cyst;
4. if the RPJ procedure should be applied in the treatment of 
prepatellar bursa.
Both orthopaedists and nuclear medicine specialists were of 
the opinion that:
Re 1. RPJ is a symptomatic treatment which can only be ap-
plied to the joints with synovial hypertrophy and preserved cartilage 
layer which protects the periosteum against the energy of ionising 
radiation. Therefore it is necessary at all times to accurately evalu-
ate the synovial membrane thickness and select pharmaceutical 
with an appropriate range of beta radiation in the soft tissue. Prof. 
Fisher reminded that this range was strictly specified in scientific 
terms and is 3.6 mm for yttrium-90, 1.1 mm for rhenium-186 and 
0.3 mm for erbium-169.
Re 2. RPJ should only be applied to stable joints with preserved 
joint capsule.
Re 3. Results of popliteal cyst treatment are questionable. 
Despite the reports in the literature (mainly Modder et al., 1995) 
concerning the efficacy of this treatment following the injection 
of an isotope to the Baker’s cyst, PG does not recommend ap-
plication of RPJ in this group of patients. On the other hand, Prof. 
Fisher pointed out that good effects can be achieved in the case 
of patients with preserved check-valve mechanism which can be 
verified by holding down the cyst with the ultrasound head and 
observing the flow of fluid.
Re 4. Based on his own experience and on account of the high 
risk of complications, PG does not recommend radiosynoviorthe-
sis for treatment of bursas.
The safety of radionuclide joint treatment was the central 
topic of the guest lecture “60 years of intra-articular radionuclide 
therapy radiosynovectomy — a safe procedure?” by Prof. Man-
fred Fisher (MF) of the Medical University in Kassel (Germany). 
Based on several dozen years of experience in radiosynovec-
tomy in Germany, MF stressed that the essential prerequisite 
for successful and safe radionuclide joint treatment is proper 
qualification of patients. It should always be remembered that it 
is a symptomatic treatment aimed at destroying the hypertrophic 
synovium membrane stimulated due to the inflammation, with the 
preservation of the other structural components. Intra-articular 
administration of radionuclides should not be applied in the case 
of patients for whom there is a possibility of contact between 
radiocolloid with the bone tissue, thus it is always necessary to 
perform a functional assessment, and additionally to determine the 
morphological condition of the joint. Damaged cartilage, accom-
panied by uncovering of the bone tissue in the joint is an absolute 
contraindication for radionuclide treatment on account of the high 
risk of local bone necrosis. It should be remembered here that 
bone necrosis is caused by a number of other factors, such as: 
trauma, hemoglobinopathies, caisson disease, metabolic disor-
ders (hypercortisolaemia, hyperlipidaemia), acute and chronic 
renal failure, post-burn conditions and others (Mirzai et al., 1999). 
MF pointed out that if radiopharmaceutical is properly selected, 
there is no possibility of damaging the bone layer as the range 
of beta radiation within the soft tissue is strictly specified for each 
radionuclide, and the absorbed dose of radiation on the bone 
surface is smaller than that absorbed during frequently applied 
radiotherapy procedures. Professor referred to the experimental 
studies of Makel et al. concerning histological examination of le-
sions with the chondrocytes sampled from the articular surface in 
rabbits following intra-articular injection of holmium-166 solution. 
Over the several dozen years of application of this method in 
Germany and Europe the best effects of treatment were achieved 
in the case of patients with early-stage reactions within the joints. 
Therefore, RPJ is now applied in Germany only to Class I and II 
patients according to the Steinbrocker functional classification of 
joints in RA and/or according to the criteria of the American Rheu-
matism Association. From among the diagnostic methods used 
for evaluation of the intensity of inflammatory processes within 
joints in patients scheduled for radionuclide treatment, MF recom-
mended three-phase bone scintigraphy, radiological examination 
and ultrasound scanning. MF referred to the studies of Avral 
(2005) and Conaghan (2010) to point out that the recurrence of 
articular effusion is the most important indicator among a range of 
predictors of adverse development of inflammatory lesions within 
the knee joint which make it necessary to implant an articular 
prosthesis. When discussing the safety of radionuclide synovec-
tomy, Prof. Fisher presented the results from the registration of 
adverse effects of preparations used for radiosynovectomy in 
the years 1990–2010. Only 28 serious adverse events (SAE) and 
40 complications described as non-serious cases were reported 
for about 831 000 radiosynovectomy procedures. These SAEs in-
cluded 17 cases of acute articular infections which depend on the 
injection method, and not on the administration of a radioactive 
isotope. According to MF, there are few medical procedures with 
such positive safety profile.
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A wide range of practical aspects were discussed between 
the lectures. 
Prof. Czubak pointed out that one of the serious orthopaedic 
problems is the recurrent effusion in the joints following arthroplasty 
and asked if the radionuclide method could be used in this group 
of patients. Both Prof. Królicki and Prof. Fisher emphasized that 
RPJ is very effective in such cases, but it is necessary to observe 
the rule that intra-articular administration of a radionuclide should 
not take place until 6 months from the date of orthopaedic surgery. 
Prof. Fisher stressed that in Germany the group of patients who 
underwent RPJ after total arthroplasty is very large, the effects are 
positive and orthopaedists readily work together nuclear medicine 
specialists in this respect as in these cases RPJ often helps to 
eliminate the need for a complicated and costly re-operation. 
One of the practical questions addressed the issue who can 
administer radionuclides intra-articularly. LK explained that radio-
nuclides should be administered by a physician having necessary 
skills and experience. Given the fact that a radioactive substance 
is administered and bearing in mind the possibility of more seri-
ous complications compared to intra-articular administration of 
steroids or other medications, a radionuclide should be injected 
after it is confirmed that the needle is inside the joint, preferably 
based on ultrasound scanning results. Radionuclide can be in-
jected by an orthopaedist, rheumatologist or another physician and 
it is not required that the injection should be performed by a nuclear 
medicine specialist. On the other hand, the procedure should take 
place in a nuclear medicine institute or laboratory as only such 
units are adapted for proper handling of radioactive isotopes. It 
is also necessary to work together with a nuclear medicine spe-
cialist who is responsible for the selection of a radionuclide and 
dose and must be present during the injection, if it is performed 
by another physician.
Another issue discussed by the participants was the variety of 
nosological entities which lead to arthritis and their diverse clinical 
classifications. It was noted that neither pain nor the width of the 
hypertrophic synovial membrane should be used as guidelines for 
qualifying patients for RPJ. Prof. Czubak pointed out that pa-
tients should be qualified based on an accurate diagnosis of the 
aetiology of arthritis and criteria applicable to a given nosological 
entity. Dr Płazińska stressed that patients referred for RPJ by rheu-
matologists are only treated for the joints affected by acute-stage 
arthritis. Only patients for whom the inflammatory process within 
the soft tissue was confirmed by scintigraphy results are qualified 
for the RPJ therapy. On the other hand, Prof. Fisher again pointed 
out the fact that in Germany, following a period of wide application 
of synoviorthesis in the case of all patients affected by pain and 
effusions in the course of osteoarthritis, currently only early-stage 
patients, i.e. patients with intense bone lesions (osteophytes, joint 
deformities) are qualified for the procedure.
As the joints are immobiliser during the RPJ procedure, 
also thromboprophylactic measures were discussed. In some 
centres all patients, who undergo radionuclide treatment of the 
knee joints, receive low molecular weight heparin, while in other 
centres it is not used at all. According to both Prof. Fisher, Prof. 
Czubak and Prof. Królicki, there is no need for obligatory applica-
tion of anticoagulants in all patients under treatment, while special 
attention should paid to patients with a high risk of embolism. It 
was recommended to determine the risk of potential embolic 
complications as part of the qualification procedure and apply 
Fraxiparine in patients with metabolic disorders with a history of 
thromboembolic events or other risk factors. At the same time Prof. 
Fisher noted that total immobilisation is not recommended even 
during the treatment of the knee joints. On the contrary, patients are 
encouraged to use toilet on their own or move their toes, while the 
knee joint remains immobile.
The closing speech was given by Prof. Jarosław Czubak who 
represented orthopaedists and Prof. Leszek Królicki who repre-
sented nuclear medicine specialists. Both professors extended 
a hearty thank you to the organizer of the meeting, Dr Toth, for 
the opportunity to learn about the most recent achievements in 
radiosynovectomy of the peripheral joints and to exchange experi-
ence and information. Prof. Czubak noted that such meetings are 
of vital importance as the extensive development of radionuclide 
methods makes it necessary for different specialists to expand their 
knowledge of nuclear medicine. Radiosynovectomy shows that 
this method is a very valuable add-on treatment for traditional 
therapies and should be used on a wider basis. The most important 
factors underlying the efficacy of RPJ include proper qualification 
of patients based on the nosological entity and progress of the 
disease, treatment of early-stage joint lesions, selection of proper 
radiopharmaceuticals and their doses, treatment control based on 
uniform criteria. In order to achieve this, physicians dealing with 
joint diseases and nuclear medicine specialists should closely 
work together. As noted by Prof. Królicki, the number of scintigra-
phy examinations in Poland is 7 times as low compared to other 
European countries and therefore such meetings are highly called 
for and should also be organised in the future.
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